Background: Amplification of HER2 is seen in 20-30% of breast cancer cases. Measurement of HER2 gene amplification appears to be of vital importance in planning the treatment schedule for patients with breast carcinoma. The aim of our study was to evaluate HER2 amplification status in malignant and benign breast tumors by differential PCR (dPCR).
Introduction
The HER2 gene, also known as c-ERBB2, is a member of the erbB family located on chromosome 17 (q21-22) and encodes a 185 kDa transmembrane protein (1) (2) (3) . HER2 gene frequently undergoes amplification and overexpression in breast cancer cases (4, 5) , leading to disease recurrence and reduced overall survival (6) (7) (8) (9) . Human breast tumors have different behaviors among HER2 gene copy number ranges of 1, 2-5, 5-20, and >20. HER2 amplification and protein overexpression are strongly correlated with node-positive breast carcinomas and overall reduction in disease-free interval (3, 10) . In addition, several studies have found HER2 gene amplification as a marker of appropriate response chemotherapy agents, but resistant to endocrine therapy (11) . Furthermore, it has been demonstrated that only HER2-amplified breast cases are sensitive to Trastuzumab (an anti-HER2 monoclonal antibody) (12) . Thus, measurement of HER2 gene amplification appears to be crucial in planning the treatment schedule for patients with breast carcinoma. There are different methods for detection of gene amplification, including Southern hybridization; Polymerase Chain Reaction (PCR) (competitive differential or real time) or Fluorescence In Situ Hybridization (FISH) (13) . Microgram quantities of high quality DNA is required to use on southern blot or dot blot hybridization methods, lasting several days to obtain the results. Tumor samples are usually obtained either by biopsy (or aspiration), or by micro-section from paraffin-embedded archival tissues; therefore, it is not easy to get enough amount of DNA, in order to perform southern blot or dot blot hybridization. Real-time PCR is a very accurate and useful method for detection of gene amplification, however, it has two main disadvantages including the cost of the test, which is substantially higher than conventional PCR, and the need for professionally trained real-time PCR analyzers, which are currently beyond the means of many laboratories (14) . Differential PCR (dPCR) is a powerful method which is performed quickly, and could be applied to propagate DNA from small amounts of samples. Indeed, dPCR is a semi-quantitative assay for the coamplification of a target and a reference gene in the same reaction tube (6) . This technique is capable of detecting amplification in specific target genes as low as two-fold (15) . dPCR-based detection of gene amplification has been demonstrated for several oncogenes (16). The semi-quantitative level of the target gene amplification is seen by the ratio between the intensity of the two PCR product bands visualized on the electrophoresis gel. The relative ratio of interest target gene to the single copy reference gene can be calculated with a suitable software or gel densitometry system. In this study, reliable measurement of HER2 amplification was carried out followed by the optimization of two genes (HER2 and INF-γ) co-amplification. HER2 gene amplification frequency was analyzed in 71 DNA samples extracted from breast tumour specimens in Isfahan province, Iran. This study describes a simple, robust, and highly sensitive differential Polymerase Chain Reaction (PCR) as a method for detecting HER2 amplification in a routine pathology laboratory.
Materials and Methods

Tissue
Tumor samples were immediately stored in liquid nitrogen after tissue incision in surgery and then stored at -70 °C. 0.1-0.5 g of the frozen tissue specimens were disrupted using mortar and pestle along with liquid nitrogen and then homogenized using appropriate syringe. The genomic DNA was extracted using the phenol/chloroform extraction procedure (17) . DNA concentration and quality of the extracted DNA was measured by spectrophotometer and gel electrophoresis, respectively. DNA was also extracted from archival formalin-fixed and paraffinembedded tissues, although an extra step of xylene extraction was required for these specimens. The removal of xylene was carried out as follow: the tissues was fixed in 10% buffered formalin for 24 h at room temperature and then processed according to routine pathological procedures. A microtome was used in order to make several 8-10 µm cryosections of 5-10 mm sections of these tissues (about 5-10 sections). These tumor sections were then soaked in 1ml of xylene for 5 min, and spun for 5 min at 13000 rpm. The pellet was washed three times with 1 ml of ethanol and spun for 5 min at 13000 rpm. The supernatant was discarded and the pellet was dried for at least 30 min then dissolved in a 5-20 ml of water (16) . All DNA samples were diluted to the same concentration of 50 ng/µl.
PCR Primers
The sequences of the HER2 and INF-γ genes were achieved from NCBI nucleotide database. The Oligo 7 software was used to design and also check the specificity of the primer sets with the following sequences: HER2 forward primer: 5' -CCTCTGACG-TCCATCATCTC-3' and HER2 reverse primer: 5'-ATCTTCTCGTGCCGTCGCTT-3', amplifying a 100 bp fragment of HER2 gene exon. INF-γ forward primer: 5'-TCTTTTCTTTCCCGATAGGT-3' and INF-γ reverse primer: 5'-CAGGGATGCTCTTCGA CCTC-3', amplifying a 150 bp fragment the interferon γ gene exon (1).
PCR Conditions
DNA amplification was carried out in duplicate for all samples in the Eppendorf Mastercycler AG22331 PCR device. Each 25 reaction mixture contained 2 µl of each primer (50 pmol), 2.5 µl of Taq polymerase buffer, 2 µl of DNA (100 ng), and 16 μl of PCR water. Two control samples that contained all the reagents but no target DNA were included with each batch. The reaction mixtures were prepared and kept on ice until the heating block of the thermal cycler reached the denaturation temperature (94 °C). The PCR amplification was carried out at 94 °C for 10 minutes and then subjected to 35 amplification cycles of 1 minute at 94 °C, 1 minute at 58.4 °C, and 1 minute at 70 °C. These steps were followed by a final extension at 72 °C for 7 minutes.
Differential PCR Amplification products were separated by electrophoresis using a 2.5% metaphor agarose gel, stained with ethidium bromide and visualized by ultraviolet illumination. The gel images were captured using a CCD camera linked to an image processing system. The intensities of the HER2 and INF-γ bands were determined for each specimen by the imageJ software. The results were expressed as a ratio: intensity of the HER2 band/intensity of the INF-γ band. The determined ratios for the tumor samples were converted into a measure of gene amplification. In this study, the 
Results
Differential PCR was performed for seventy one malignant and benign breast cancer cases. Five normal breast tissues were also included in this study. In next step, 100 and 150 bp PCR products were resolved clearly using 2.5% metaphor agarose. In all normal samples the intensity of the INF-γ band was greater than that of the HER2 band. Each sample was analyzed at least twice and each replicate gave concordant results. The intensity ratios of 100 to 150 bp bands were calculated. The ratio 1 to 2.0 indicates the absence of any gene amplification. On the other hand, the intensity ratio greater than 2 indicates the gene amplification. All DNA samples isolated from forty three malignant breast cancer tissues were analyzed for HER2 amplification. In samples with no HER2 amplification which constituted the majority of cases, the ratio of target to the control gene was almost 1, while this value was between 2 to 6 for the tissues showing which implies HER2 gene amplification (Figure 1 ). According to the electrophoresis gel analyses using ImageJ software, 32 out of 43 (~74%) malignant samples had a normal HER2 copy number, and 11 out of 43 (~26%) showed HER2 amplification ( Figure 2 ). The distribution of HER2-amplified samples based on categories of malignant breast tumors is listed in Table 1 . From twenty eight benign tumor samples analyzed in this study, two specimens (7%) showed HER2 amplification (Figure 3) . A summary of the histopathologic findings is presented in Table 2 . 
Discussion
Amplification is the only structural alteration of the HER2 gene observed in human cancers (18) and is found in 20-30% of breast tumors (19, 20 HER2 overexpression in 171 breast cancer patients and determined their impact on the risk of death and metastasis after a nearly 10-year follow-up. They showed that amplification-dependent HER2 overexpression is associated with an increased risk of death (P=0.01), while no relationship was found between HER2 overexpression with no amplification and the rate of mortality (P =0.54). Moreover, HER2 amplification was correlated with a higher risk of multifocal metastases (P=0.02), explaining the role of HER2 in cancer invasiveness (21) . Therefore, measurement of HER2 gene amplification would be a better indicator comparing with its overexpression in breast cancer patients. The aim of this study was to present a robust differential PCR assay for detection of HER2 amplification in human DNA. In dPCR method, numerical results are generated by an image analysis system; therefore, this technique provides objective analysis of a molecular marker, making it a good candidate for development as a routine pathology test. The sensitivity of this technique and the small sizes of PCR products make the protocol amenable to the analysis of small amounts of degraded DNA (16) . In this study, 11 out of 43 (~26%) breast tumors showed HER2 amplification, exhibiting low and medium levels (two to six folds) of HER2 amplification detected by ImageJ software. Twenty eight benign biopsies were also studied, showing 2 cases of HER2 amplification (~7%). In 1997, Jennings et al. reported the amplification of HER2 in ~26% of breast tumor samples (6) that is identical to outcome of this study. Despite this similarity, other studies using dPCR method found different outcomes. In 1999, Deng et al. observed HER2 amplification among 35% of their cases (22) , which is consistent with our previously published paper reporting 35% rate of HER2 amplification (5) . In three various studies the rate of HER2 amplification using differential PCR were 13.7%, 16.7%, and 15%, respectively (23) (24) (25) . Invasive breast cancer and/or atypical hyperplasia could be developed in some women with benign breast disease (BBD). In such cases histopathological predictions are not efficient and informative enough because of inter-and/or intra-observer variability, differences in pathologic criteria, and limitations in the quantity of tissue available for examination (26), therefore, detection of possible genetic alterations in BBD using molecular techniques could be considered as a promising method to improve risk prediction. These techniques may also be appropriate for rapid detection of gene amplification as an important parameter in determining a standard chemotherapeutic regimen. 
Conclusion
Differential PCR method can be used routinely and clinically as a rapid, cheap and easy PCR-based protocol for the assessment of gene copy number in both fresh and archival samples. It is especially recommended to be used along with golden standard technique of HER2 evaluation, i.e. IHC. These assessments are clinically useful to determine the therapeutic regimens as well as the biological characteristics of breast cancer.
